Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 3Primary Myelofibrosis 1Pancreatic Neoplasms 1Leukemia 1Hematologic Diseases 1Colorectal Neoplasms 1Bone Marrow Diseases 1

Interventions

Brentuximab Vedotin 20Rituximab 10pirtobrutinib 7dacetuzumab 7Doxorubicin 6ruxolitinib 5Vincristine 5Prednisone 5Lenalidomide 5Cyclophosphamide 5ponatinib 4Imatinib Mesylate 4Dexamethasone 4Bendamustine Hydrochloride 4Azacitidine 4nilotinib 3lintuzumab 3Bortezomib 3vosaroxin 2venetoclax 2spartalizumab 2pomalidomide 2ibrutinib 2Rifampin 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2KW-2478 2Ifosfamide 2Gemcitabine 2Etoposide 2Dacarbazine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Diseases × simtuzumab × Clear all
NCT01369498 2020-07-01

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Gilead Sciences

Phase 2 Completed
54 enrolled 16 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡